International Stem Cell (ISCO) Total Non-Current Liabilities (2011 - 2022)
International Stem Cell (ISCO) posted quarterly Total Non-Current Liabilities of $5.4 million for Q3 2022, up 8.01% year-over-year from $5.0 million in Q3 2021, and down 2.53% quarter-over-quarter from $5.5 million in Q2 2022.
International Stem Cell (ISCO) Total Non-Current Liabilities (2011 - 2022) Analysis & Trends
International Stem Cell (ISCO) has reported Total Non-Current Liabilities for 12 consecutive years, with $5.4 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Total Non-Current Liabilities rose 8.01% year-over-year to $5.4 million; the TTM figure through Sep 2022 stood at $5.4 million (up 8.01% YoY), while the FY2021 annual figure was $5.2 million, down 1.62% from the prior year.
- Total Non-Current Liabilities eased to $5.4 million in Q3 2022 per ISCO's latest filing, from $5.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $6.7 million in Q3 2018 and bottomed at $3.5 million in Q4 2018.
- Historically, Total Non-Current Liabilities has averaged $5.3 million across 5 years, with a median of $5.4 million in 2020.
- Annual changes were most pronounced in 2018 — Total Non-Current Liabilities soared 108.3% — and 2019, when it dropped 18.49%.
- International Stem Cell's Total Non-Current Liabilities stood at $3.5 million in 2018, then jumped by 42.32% to $5.0 million in 2019, then increased by 6.38% to $5.3 million in 2020, then declined by 1.62% to $5.2 million in 2021, then grew by 3.06% to $5.4 million in 2022.
- Business Quant data shows ISCO's Total Non-Current Liabilities at $5.4 million in Q3 2022, $5.5 million in Q2 2022, and $5.7 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 9.32 Bn |
| 10 | International Stem Cell | 3.20 Mn | 2.11 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 5.39 Mn |
| Jun 30, 2022 | 5.53 Mn |
| Mar 31, 2022 | 5.71 Mn |
| Dec 31, 2021 | 5.23 Mn |
| Sep 30, 2021 | 4.99 Mn |
| Jun 30, 2021 | 5.62 Mn |
| Mar 31, 2021 | 6.42 Mn |
| Dec 31, 2020 | 5.32 Mn |
| Sep 30, 2020 | 5.39 Mn |
| Jun 30, 2020 | 6.09 Mn |
| Mar 31, 2020 | 5.42 Mn |
| Dec 31, 2019 | 5.00 Mn |
| Jun 30, 2019 | 4.60 Mn |
| Mar 31, 2019 | 4.33 Mn |
| Dec 31, 2018 | 3.51 Mn |
| Sep 30, 2018 | 6.70 Mn |
| Jun 30, 2018 | 5.64 Mn |
| Mar 31, 2018 | 4.71 Mn |
| Dec 31, 2017 | 1.69 Mn |
| Sep 30, 2017 | 4.29 Mn |